Date / Time | Nov. 13 (Thu), 09:00-10:30 | |
---|---|---|
Room | Vista 1 | |
Chair(s) |
Yoon Jun Kim (Seoul National University, Korea)
Hyung Joon Kim (Chung-Ang University, Korea) |
|
Speakers | 09:00-09:10 | The CMH journey: Global growth and author guidance Yeonjung Ha (CHA University, Korea) |
09:10-09:30 | CMH clinical research highlight–Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment Do Seon Song (The Catholic University of Korea, Korea) | |
09:30-09:50 | CMH clinical trial highlight–Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial Yao-Chun Hsu (I-Shou University, Taiwan) | |
09:50-10:10 | CMH epidemiologic research highlight–Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study Jeong-Hoon Lee (Seoul National University, Korea) | |
10:10-10:30 | CMH multinational research highlight–Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306) Xiaolong Qi (Southeast University, China) |
Date / Time | Nov. 13 (Thu), 10:50-12:20 | |
---|---|---|
Room | Vista 1 | |
Chair(s) | Sook-Hyang Jeong (Seoul National University, Korea) | |
Speakers | 10:50-12:20 | The liver odyssey: Four decades of progression and hope Joong-Won Park (Myongji Hospital, Korea) |
Date / Time | Nov. 13 (Thu), 13:20-14:50 | |
---|---|---|
Room | Vista 1 | |
Chair(s) |
Young-Suk Lim (University of Ulsan, Korea)
Ji Hoon Kim (Korea University, Korea) |
|
Speakers | 13:20-13:42 | Risk-stratified prophylaxis for HBV reactivation in patients receiving biological agents Pin-Nan Cheng (National Cheng Kung University, Taiwan) |
13:42-14:04 | Management of anti-HBc or HBsAg-positive donors and recipients in liver transplantation Deok Gie Kim (Yonsei University, Korea) | |
14:04-14:26 | Risks and benefits of statins and DOACs in cirrhotic patients with cardiovascular disease Ho Soo Chun (Ewha Womans University, Korea) | |
14:26-14:48 | Current controversies in HCC risk and surveillance after SVR in HCV-infected patients Ryosuke Tateishi (The University of Tokyo, Japan) | |
14:48-14:50 | Q&A |
Date / Time | Nov. 13 (Thu), 15:10-16:40 | |
---|---|---|
Room | Vista 1 | |
Chair(s) |
Si Hyun Bae (The Catholic University of Korea, Korea)
Sang Hoon Ahn (Yonsei University, Korea) |
|
Speakers | 15:10-15:32 | Korean nationwide population-based study using the National Health Information Database Han Ah Lee (Chung-Ang University, Korea) |
15:32-15:54 | Taiwanese nationwide database for chronic viral hepatitis Mei-Hsuan Lee (National Yang Ming Chiao Tung University, Taiwan) | |
15:54-16:16 | Common data models for real-world data analysis Rae Woong Park (Ajou University, Korea) | |
16:16-16:38 | The genetic architecture of hepatocellular carcinoma: Insights from genome-wide association studies Eric Trepo (Universite Libre de Bruxelles, Belgium) | |
16:38-16:40 | Q&A |
Date / Time | Nov. 14 (Fri), 08:30-10:00 | |
---|---|---|
Room | Vista 2 | |
Chair(s) |
Han Chu Lee (University of Ulsan, Korea)
Jae Young Jang (Soonchunhyang University, Korea) |
|
Speakers | 08:30-08:52 | The priority decision for subsequent systemic therapy after first-line failure of ICI-based regimens for HCC Arndt Vogel (University of Toronto, Canada) |
08:52-09:14 | Liver-directed therapy combined with IO/TKI for locally advanced and metastatic HCC Zhen-Wei Peng (Sun Yat-sen University, China) | |
09:14-09:36 | Role of radiotherapy for advanced-stage HCC in the era of IO Jeong Il Yu (Sungkyunkwan University, Korea) | |
09:36-09:58 | Efficacy and safety of ICI-based treatment for Child-Pugh B HCC Jean-Charles Nault (Université Sorbonne Paris Nord, France) | |
09:58-10:00 | Q&A |
Date / Time | Nov. 14 (Fri), 10:20-11:50 | |
---|---|---|
Room | Vista 2 | |
Chair(s) |
Jung-Hwan Yoon (Seoul National University, Korea)
Won-Il Jeong (KAIST, Korea) |
|
Speakers | 10:20-10:50 | Models for hepatitis B and the associated liver cancers Kyun-Hwan Kim (Sungkyunkwan University, Korea) |
10:50-11:20 | Preclinical MASH studies Sang Geon Kim (Dongguk University, Korea) | |
11:20-11:50 | Cancer immunotherapy research Tae-Jin Kim (Korea Institute of Radiological & Medical Sciences, Korea) |
Date / Time | Nov. 14 (Fri), 13:20-14:50 | |
---|---|---|
Room | Vista 2 | |
Chair(s) |
Jia-Horng Kao (National Taiwan University, Taiwan)
Moon Seok Choi (Sungkyunkwan University, Korea) |
|
Speakers | 13:20-13:42 | Early predictors of hepatitis B relapse after antiviral cessation Cheng-Hao Tseng (I-Shou University, Taiwan) |
13:42-14:04 | Biomarkers for monitoring disease progression in MASLD Nabuharu Tamaki (Red Cross Hospital Tokyo, Japan) | |
14:04-14:26 | Imaging markers predicting response to IO in HCC Subin Heo (University of Ulsan, Korea) | |
14:26-14:48 | Histological markers for differential diagnosis of liver tumors and inflammatory conditions Haeryoung Kim (Seoul National University, Korea) | |
14:48-14:50 | Q&A |
Date / Time | Nov. 14 (Fri), 15:10-16:40 | |
---|---|---|
Room | Grand 1 | |
Chair(s) |
Neung Hwa Park (University of Ulsan, Korea)
Sungbum Cho (Chonnam National University, Korea) |
|
Speakers | 15:10-15:32 | Chronic hepatitis B: Antiviral strategy Won-Mook Choi (University of Ulsan, Korea) |
15:32-15:54 | Chronic hepatitis C: Antiviral strategy Young Kul Jung (Korea University, Korea) | |
15:54-16:16 | MASLD: Current and potential new treatments Won Sohn (Sungkyunkwan University, Korea) | |
16:16-16:38 | Liver cirrhosis: Complications and specific management Do Seon Song (The Catholic University of Korea, Korea) | |
16:38-16:40 | Q&A |